评价他克莫司治疗全身型重症肌无力（MG）的疗效及不良反应

摘要

Objective To evaluate systemic tacrolimus treatment of myasthenia gravis (MG) efficacy and adverse reactions. Methods June 2013 to June 2014 in our hospital for treatment of systemic MG 50 patients, all patients are treated with tacrolimus, record the total patients after 1,3,6 months effectiveness and adverse reactions during treatment emerged. ResultsTreatment of systemic tacrolimus MG significant clinical effect, and with time, the total efficiency of the treatment of patients gradually increased, which 1,3,6 months of treatment in patients with total efifciency of 82%, respectively, 90 % and 92%. However, the course of treatment, blood sugar, leukopenia and dizziness is the most important adverse reactions in patients. ConclusionThe treatment of systemic tacrolimus MG signiifcant effect, but in the course of treatment the patient needs to strengthen monitoring, control the incidence of adverse reactions.%目的：评价他克莫司治疗全身型重症肌无力（MG）的疗效及不良反应。方法选取2013年6月～2014年6月期间在我院接受治疗的全身型MG患者50例，所有患者均以他克莫司进行治疗，记录患者治疗后1、3、6个月的总有效率及在治疗过程中所出现的不良反应。结果他克莫司治疗全身型MG临床效果显著，其中患者的1、3、6个月治疗总有效率分别为82%、90%与92%。治疗过程中，血糖升高、白细胞减少与头晕是患者最主要的不良反应。结论他克莫司治疗全身型MG效果显著，但在治疗过程中需加强对患者的监测，控制不良反应的发生。